Fig. 6.
Induction of systemic antitumor immunity by combined cryoimmunotherapy. Mice were inoculated with D122-luc-5.5 cells and treated as previously described. Surviving mice (80–95 days following amputation of the primary tumor-bearing foot) and a control group of six age-matched naïve mice were rechallenged with 2 × 105 D122-luc-5.5 cells in the other foot. Spleens were removed 45 days later, and cells were stimulated with irradiated D122-luc-5.5 cells for 5 days. Further, they were incubated with the following 35S-methionine-labeled target cells: D122-luc-5.5 (a), Kb39.5 (b), and B16-F10.9 (c). CTL assays were carried out at four effector:target ratios ranging from 100:1 to 12.5:1, in triplicates. d Specific killing of D122-luc-5.5 at effector:target ratio of 100:1 is shown for the different CpG-ODN concentrations. n = 5–8 mice per group; *P < 0.05; **P < 0.001; ***P < 0.0001